Skip to content

Evaluation of Gynecological Acceptability of a Health Care Product

Evaluation of Cutaneous Acceptability and Genital Mucosa Acceptability of a Health Care Product (Intimate Gel), and Interference of Microbiota and pH Around the Vaginal Introit, With Instrumental Evaluation of the Mucosa Hydratation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04247022
Enrollment
74
Registered
2020-01-29
Start date
2021-04-09
Completion date
2021-07-15
Last updated
2021-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic Vaginitis, Vaginal Diseases

Brief summary

The research will be conducted with a product for use in the intimate region in up to 75 research participants who will use the investigational product for 28 ± 2 days. Will be evaluated and followed up throughout the study by a gynecologist to verify the safety and effectiveness of the product and possible adverse events. The study will evaluate the non-interference of a topical use product on the intimate area, helping to preserve the natural defenses. In addition, the epithelial hydration and pH of the intimate area will be evaluated.

Detailed description

74 female participants, 18 to 59 years of age, healthy with complaints of vaginal dryness. The subjects will be submitted to gynecological evaluation in which pH measurements, hydration measurements and bacterioscopic collection will be performed. Then they will be guided to answer the questionnaires of Perceived Efficacy and Quality of Sexual Life. Next, participants will receive the product for home use, under real conditions of use, for 28 ± 2 days. After 28 ± 2 days of use, subjects will return to the institute, and undergo further evaluations with the gynecologist. New pH measurements, hydration measurements (chronometry), bacterioscopic collection will be performed and the participants will answer the Perceived Efficacy and Quality of Sexual Life questionnaires.

Interventions

OTHERHealth care product (intimate gel)

heath care product (intimate gel) for home use, under real conditions of use, for 28 ± 2 days

Sponsors

Herbarium Laboratorio Botanico Ltda
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Clinical trial, single-arm

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 59 Years
Healthy volunteers
Yes

Inclusion criteria

* Health volunteers * Non-injured mucosa in the test region; * Agreement to comply with safety guidelines to minimize the risk of contamination to COVID-19; * Agreement to perform molecular testing to detect COVID-19 to enter the study; * Agreement to adhere to study procedures and requirements and attend the institute on the day(s) and time(s) determined for the evaluations; * Ability to consent to their participation in the study; * Age from 18 to 59 years old (25 participants from 18 to 39 years old, 25 participants from 40 to premenopause and 25 participants in climacteria); * Female participants; * Vaginal dryness (slight minimum) - according to questions from the gynecologist.

Exclusion criteria

* Participants who belong to the risk group for COVID-19, that is, aged over 60 years, with diabetes, with chronic cardiovascular, renal and respiratory problems, immunosuppressed or other conditions that the physician deems to belong to the risk group; * Participants who have COVID-19, or who have symptoms indicative of the disease in the last 14 days, such as temperature above 36.8°C, fever, cough, shortness of breath, loss of smell, loss of taste and fatigue; * Pregnancy or breastfeeding; * Skin pathology in the area of application of the product; * Diabetes Mellitus type 1; insulin-dependent diabetes; presence of complications due to diabetes (retinopathy, nephropathy, neuropathy); presence of diabetes-related dermatoses (plantar ulcer, lipoid necrobiosis, annular granuloma, opportunistic infections); history of episodes of hypoglycemia, diabetic ketoacidosis and/or hyperosmolar coma; * Current use of the following medications for topical or systemic use: corticosteroids, immunosuppressants and antihistamines; * Skin diseases: vitiligo, psoriasis, lupus, atopic dermatitis; * History of reaction to the category of the tested product; * Other diseases or medications that may directly interfere with the study or endanger the health of the research participant.

Design outcomes

Primary

MeasureTime frameDescription
Perceived Hydration28 ± 2 daysEvaluate the perceived hydration through a subjective questionnaire
Hydration (device)28 ± 2 daysEvaluate the hydration, through a hydration measurements by chronometry.

Secondary

MeasureTime frameDescription
Natural defenses preservation (pH)28 ± 2 dayspH measurements
Natural defenses preservation (microbiota)28 ± 2 daysbacterioscopic collection

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026